Dr. Keith C. Charles, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Southern California Keck School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,583
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of Southern California Keck School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME0069013
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Mid Florida Eye Center PA (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,583
- Services billed
- 5,429
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Photography of the retina | 1,281 | 1,245 |
| Established patient complete exam of visual system | 1,268 | 1,235 |
| Imaging of retina | 835 | 806 |
| Measurement of corneal curvature and depth of eye | 600 | 210 |
| Established patient problem focused exam of visual system | 409 | 308 |
| Analysis of substance using immunoassay technique, multiple step method | 390 | 191 |
| Microfluid analysis of tears | 388 | 191 |
| Established patient office or other outpatient visit, 20-29 minutes | 383 | 219 |
| Removal of cataract with insertion of prosthetic lens | 332 | 209 |
| Closure of tear duct opening using plug | 226 | 212 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Mount Dora, FL | 590 |
| Prednisolone Acetate Other prescribers in Mount Dora, FL | 460 |
| Timolol Maleate Other prescribers in Mount Dora, FL | 292 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Mount Dora, FL | 263 |
| Fluorometholone Other prescribers in Mount Dora, FL | 169 |
| Brimonidine Tartrate Other prescribers in Mount Dora, FL | 116 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Mount Dora, FL | 85 |
| Lumigan (bimatoprost) Other prescribers in Mount Dora, FL | 80 |
| Erythromycin (erythromycin base) Other prescribers in Mount Dora, FL | 78 |
| Tobramycin-Dexamethasone (tobramycin/dexamethasone) Other prescribers in Mount Dora, FL | 66 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 11 payments worth $262 in total to this clinician.
| AbbVie Inc. | $91.49 |
|---|---|
| Dompe US, Inc. | $90.20 |
| Astellas Pharma US Inc | $28.01 |
| Bausch & Lomb Americas Inc. | $20.00 |
| Mallinckrodt Hospital Products Inc. | $16.59 |
| Apellis Pharmaceuticals, Inc. | $15.92 |
| Food and Beverage | $262 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $30,519 in research payments for these studies, mostly to the institutions running them.
- Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Oyster Point Pharma, Inc. · Completed · NCT06349759 - Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Oyster Point Pharma, Inc. · Completed · NCT06542497
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.